- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Altimmune Inc (ALT)
Assess today's live Altimmune Inc (ALT) share price, performance and insights using our live NASDAQ: ALT stock exchange data.
Analyse the historical data and Altimmune Inc share price performance charts on this page. Our technical summary section provides analysis on Altimmune share price buy/sell indicators using real-time data (or discuss the Altimmune (ALT) stock price today with other investors in the Altimmune NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ ALT share price (ISIN: US02155H2004) to enhance your trading decisions with our free investment tools and resources.
What Is the Altimmune Inc Share Price Today?
The Altimmune share price today is 4.54.
What Is the Stock Symbol for Altimmune Inc
The stock symbol (or 'ticker') for Altimmune Inc is "ALT."
What Stock Exchange Does Altimmune Inc Trade On?
Altimmune Inc is listed and trades on the NASDAQ stock exchange.
Is Altimmune Inc a Good Stock to Buy?
Determining whether Altimmune Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Analyse the historical data and Altimmune Inc share price performance charts on this page. Our technical summary section provides analysis on Altimmune share price buy/sell indicators using real-time data (or discuss the Altimmune (ALT) stock price today with other investors in the Altimmune NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ ALT share price (ISIN: US02155H2004) to enhance your trading decisions with our free investment tools and resources.
What Is the Altimmune Inc Share Price Today?
The Altimmune share price today is 4.54.
What Is the Stock Symbol for Altimmune Inc
The stock symbol (or 'ticker') for Altimmune Inc is "ALT."
What Stock Exchange Does Altimmune Inc Trade On?
Altimmune Inc is listed and trades on the NASDAQ stock exchange.
Is Altimmune Inc a Good Stock to Buy?
Determining whether Altimmune Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Currency in USD
4.54
+0.01(+0.11%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.48
4.64
52 wk Range
2.90
7.73
ALT is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.484.64
52 wk Range
2.907.73
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ALT Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Price Target
17.67
Upside
+289.13%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales decline in the current year
- Form 8K Altimmune Inc For: 28 January
- Investing.com
- Form 424B5 Altimmune Inc For: 28 January
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Altimmune Company Profile
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Altimmune Inc SWOT Analysis
Pemvidutide Promise | Explore pemvidutide's potential in MASH and obesity treatment, with unprecedented liver fat reduction and significant weight loss results |
Expanding Horizons | Delve into Altimmune's strategic expansion of pemvidutide applications to include alcohol use disorder and alcoholic liver disease |
Clinical Milestones | Anticipate key clinical trial outcomes, including the Phase 2b IMPACT trial for MASH, with top-line data expected in Q2 2025 |
Market Potential | Analyst price targets range from $12 to $28, with projected peak U.S. sales exceeding $2.5 billion for MASH indication alone |
Altimmune Inc Earnings Call Summary for Q2/2025
- Q2 2025 EPS of -$0.27 beats -$0.31 forecast, driving 5.62% stock rise to $3.57 in premarket trading
- Total cash increased 40% to $183.1M; R&D expenses down to $17.2M from $21M YoY; net loss improved to $22.1M from $24.6M YoY
- NASH treatment shows promising trial results; end-of-Phase II FDA meeting scheduled for Q4 2025
- New Board Chairman Jerry Durso appointed; company raised $88M in equity and secured $100M debt facility
- Advancing Phase II trials for AUD and ALD; 48-week NASH treatment data expected later this year
Last Updated: 12/08/2025, 14:30
Read Full TranscriptCompare ALT to Peers and Sector
Metrics to compare | ALT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipALTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −6.8x | −1.8x | −0.5x | |
PEG Ratio | −0.22 | 0.09 | 0.00 | |
Price/Book | 3.1x | 4.6x | 2.6x | |
Price / LTM Sales | 28,364.9x | 28.2x | 3.3x | |
Upside (Analyst Target) | 341.5% | 58.5% | 47.0% | |
Fair Value Upside | Unlock | 8.5% | 5.7% | Unlock |
Analyst Ratings
8 Buy
1 Hold
1 Sell
Ratings:
10 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 17.67
(+289.13% Upside)
Earnings
Latest Release
Nov 06, 2025
EPS / Forecast
-0.21 / -0.27
Revenue / Forecast
5.00K / 2.14K
People Also Watch
FAQ
What Is the Altimmune (ALT) Share Price Today?
The live Altimmune share price today is 4.54
What Stock Exchange Does Altimmune (ALT) Trade On?
Altimmune is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Altimmune?
The stock symbol (also called a 'ticker') for Altimmune is "ALT."
What Is the Current Altimmune Market Cap?
As of today, Altimmune market capitalisation is 567.30M.
What Is Altimmune's (ALT) Earnings Per Share (TTM)?
The Altimmune EPS is currently -1.06 (Trailing Twelve Months).
When Is the Next Altimmune Earnings Date?
Altimmune's next earnings report will be released on 26/03/2026.
Is ALT a Buy or Sell From a Technical Analyst Perspective?
Based on today's Altimmune moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Altimmune Stock Split?
Altimmune has split 2 times. (See the ALT stock split history page for full effective split date and price information.)
How Many Employees Does Altimmune Have?
Altimmune has 59 employees.
What is the current trading status of Altimmune (ALT)?
As of 17/02/2026, Altimmune (ALT) is trading at a price of 4.54, with a previous close of 4.53. The stock has fluctuated within a day range of 4.48 to 4.64, while its 52-week range spans from 2.90 to 7.73.
What Is Altimmune (ALT) Price Target According to Analysts?
The average 12-month price target for Altimmune is USD17.67, with a high estimate of USD28 and a low estimate of USD1. 8 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +289.13% Upside potential.
What Is the ALT Premarket Price?
ALT's last pre-market stock price is 4.67. The pre-market share volume is 20,440.00, and the stock has decreased by 0.14, or 3.09%.
What Is the ALT After Hours Price?
ALT's last after hours stock price is 4.57, the stock has decreased by 0.04, or 0.88%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.